Proceedings of the International Symposium on Polymer Therapeutics - Recent Progress in Clinics and Future Prospects, held July 13-14, 2001, in Nara, Japan.

The technology of polymer science has developed considerably during the past half-century, and this volume describes some of the aspects of this technology that will have a great impact in the future. Among these advances, for example, are gene delivery to specific disease sites and carrier polymers that respond to a stimulus or particular environment. Cancer targeted drug delivery is another focused area of this volume because of the important nature of EPR-effect of polymer drugs in tumor. Included are discussions of as many examples as possible of polymer drugs that have achieved, or are close to clinical use. The concept of "Polymer drugs" here is limited to primarily injectable and water-soluble agents, although also covered are some drugs in micellar form or liposomes.

This book is intended for students and researchers in the field of pharmacology who have particular interests in drug delivery, targeting, and formulation, as well as for clinicians such as oncologists who are interested in the field. People who work at regulatory agencies should also be aware such that drugs with great potential are being developed and will be beneficial to many patients, as well as to health insurance agencies because of improved cost effectiveness.

Les mer
Cancer targeted drug delivery is another focused area of this volume because of the important nature of EPR-effect of polymer drugs in tumor. The concept of "Polymer drugs" here is limited to primarily injectable and water-soluble agents, although also covered are some drugs in micellar form or liposomes.
Les mer
Challenges in Polymer Therapeutics.- Factors and Mechanism of “EPR” Effect and the Enhanced Antitumor Effects of Macromolecular Drugs Including SMANCS.- PEG-Adenosine Deaminase and PEG-Asparaginase.- Peginterferon alfa-2a (40KD): A Potent Long-Acting Form of Interferon alfa-2a for the Treatment of Hepatitis C.- PEG-Methioninase.- Poly-(L)-Glutamic Acid-Paclitaxel (CT-2103) [XYOTAX™], a Biodegradable Polymeric Drug Conjugate.- HPMA Copolymer Delivery of Chemotherapy and Photodynamic Therapy in Ovarian Cancer.- Drug-HPMA-HuIg Conjugates Effective Against Human Solid Cancer.- CM-Dextran-Polyalcohol-Camptothecin Conjugate.- Polymeric Micelle Drug Carrier Systems: PEG-PAsp(Dox) and Second Generation of Micellar Drugs.- An Interim Analysis of Phase I Clinical Trial of MCC-465, a Doxorubicin (DXR) Encapsulated in PEG-immunoliposome, in Patients with Metastatic Stomach Cancer.- Polymer Conjugates for Imaging.- S-Nitrosylated Polyethylene Glycol-conjugated Hemoglobin Derivative as a Candidate Material for Oxygen Therapeutics.
Les mer
Springer Book Archives
Springer Book Archives
GPSR Compliance The European Union's (EU) General Product Safety Regulation (GPSR) is a set of rules that requires consumer products to be safe and our obligations to ensure this. If you have any concerns about our products you can contact us on ProductSafety@springernature.com. In case Publisher is established outside the EU, the EU authorized representative is: Springer Nature Customer Service Center GmbH Europaplatz 3 69115 Heidelberg, Germany ProductSafety@springernature.com
Les mer

Produktdetaljer

ISBN
9781475778403
Publisert
2013-03-28
Utgiver
Vendor
Springer-Verlag New York Inc.
Høyde
235 mm
Bredde
155 mm
Aldersnivå
Research, P, 06
Språk
Product language
Engelsk
Format
Product format
Heftet